Dec 7, 2023

News provided by Share this article Share toX LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS). The study, which is part of a collaboration between Px and AstraZeneca UK, is a nationwide RWE initiative enabling any breast cancer patient in the UK to take part in the study when prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) using the OWise app. For this study two new tailored treatment-specific versions of OWise have been developed to support UK patients recently prescribed with one of the two treatments within their licenced indications. The study, called RELATE-2, evaluates the experience of patients treated with TDX-d or olaparib while using the OWise treatment-specific modules. Being led by an international team of clinical researchers, the study's Principal Investigator Dr. Sophie McGrath, a Consultant Medical Oncologist at the Royal Marsden Foundation Trust, commented, "RELATE-2 represents a new way to assess patient experiences in the real world, using a widely available, clinically-validated, cancer patient support app. I'm looking forward to gaining a detailed understanding of how patients experience the use of new treatment-specific support apps countrywide and within specific patient groups." Founder & CEO of Px, Dr. Anne Bruinvels, said, "The RELATE-2 study is an exciting novel way to conduct patient-centred Real World Evidence research. With the freely available OWise breast cancer app patients prescribed with TDX-d or olaparib can find personalized support. Also, OWise enables patients to directly consent and contribute to clinical research all within the app. OWise is designed to empower patients whilst delivering insights that can help reshape patient care." The RELATE-2 poster presented by Principal Investigator Dr. Sophie McGrath at the 2023 San Antonio Breast Cancer Symposium can be accessed here : https://pxhealthcare.com/cms/wp-content/uploads/RELATE-2-SABCS-POSTER.pdf For more information about OWise please visit https://owise.uk Access Notes here: https://pxhealthcare.com/relate-2-notes PRN Top Stories Newsletters Enter Your Email By signing up you agree to receive content from us. Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our  PRN Consumer Newsletter Privacy Notice . You can withdraw your consent at any time in the footer of every email you'll receive.Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten. Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer  PRN Consumer Newsletter Privacy Notice . Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen.En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part. Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant  PRN Consumer Newsletter Privacy Notice . Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu.Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на  PRN . Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.